Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

To study the clinical picture of all patients with GNAO1 encephalopathy detected in the Russian Federation. This publication is a multicenter study combining data from epileptological centers in Moscow, Novosibirsk, St. Petersburg, Nizhny Novgorod, Tyumen. Nine patients were included, aged 2 to 19 years, with 4 mutations. Male to female sex ratio = 5:4. 8 patients (5 with mutation c.607G>A (p.Gly203Arg), 1 - c.155A>G (Gln52Arg), 1 - c.485G>A (p.Arg162Gln)) had a variant of epileptic encephalopathy, developmental encephalopathy, 1 patient had torsion dystonia without epilepsy (mutation c.713A>G (p.Asp238Gly)). Epileptic seizures in 8 children with epileptic encephalopathy GNAO1 in 100% debuted at 1 month of life, becoming the earliest symptom of the disease. Motor development delayed in 100% of cases. Mental development was not affected only in the case of the dystonic variant. Hyperkinesis (dystonia, choreoathetosis, ballism) followed later, from 2 to 8 months. They were more severe than epilepsy. 4 patients with the c.607G>A (p.Gly203Arg) mutation developed repeated dystonic storms that were resistant to most drugs. Epilepsy in GNAO1 is difficult to treat, but temporary or complete remission is possible. Effective drug strategies for the treatment of hyperkinesis have not yet been developed. Expansion of indications for surgical therapy (DBS) of hyperkinesis in this syndrome is desirable.


M Yu Bobylova, I V Volkov, E V Gumennik, O A Rachmanina, M O Abramov, O K Volkova, T S Bayborina, A S Petrukhin. Encephalopathy GNAO1]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2023;123(1):122-130

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 36719128

View Full Text